Efficacy and safety of Exclzyme Pet for arthritis and inflammation in dogs - RCT

저자: Wangikar Pralhad B; Deshpande Anand R; Arja Avinash; Natu Kaustubh V; Magdum Ranjeet R
출처: Frontiers in veterinary science, 2026
DOI/링크: 10.3389/fvets.2026.1803915
분야 태그: #반려동물 #동물건강
정리일: 2026-07-11

TL;DR

In conclusion, Exclzyme Pet demonstrated significant efficacy in reducing clinical signs of arthritis and improving functional outcomes in dogs, with no evident safety concerns during the entire study period. These results suggest that Exclzyme Pet may serve as a safe and effective adjunctive therapy for managing canine arthritis. Nevertheless, longer-duration clinical trials with large study population are needed to confirm these findings and further elucidate the mechanisms its therapeutic effects

1. 연구 배경 및 동기

다루는 문제: A randomized, double-blind, placebo-controlled interventional pilot trial was conducted to evaluate the safety and efficacy of Exclzyme Pet in alleviating clinical symptoms associated with canine arthritis

2. 관련 연구

기존 연구 흐름: A randomized, double-blind, placebo-controlled interventional pilot trial was conducted to evaluate the safety and efficacy of Exclzyme Pet in alleviating clinical symptoms associated with canine arthritis.
이 논문의 위치: Animal Health 분야 내 기존 문헌 검토

구분	기존 연구	이 논문
주제	일반적 접근	Efficacy 중심

3. 핵심 기여

Exclzyme Pet resulted in a statistically significant reduction in scores for lameness, weight bearing, joint mobility, willingness to hold up contralateral limb, and pain by 51.96, 46.94, 48.94, 58.0, and 55.56%, respectively and demonstrated clear superiority over placebo
The overall quality of life, mood, and mobility improved significantly in the treatment group over the placebo
In conclusion, Exclzyme Pet demonstrated significant efficacy in reducing clinical signs of arthritis and improving functional outcomes in dogs, with no evident safety concerns during the entire study period

4. 제안 방법론

전체 접근 논리: A total of 26 client-owned dogs exhibiting clinical signs of arthritis were enrolled in a 30-day pilot trial, of which 23 completed the study
단계: Subjects were randomly allocated to either the treatment group (N = 12), receiving Exclzyme Pet (2 g per dog, administered orally twice daily on an empty stomach with water), or the placebo group (N = 11), receiving maltodextrin at an equivalent dose.

5. 실험 설정

항목	내용
대상/재료	A total of 26 client-owned
처리 조건	Subjects were randomly allocated to either the treatment group (N = 12), receiving Exclzyme Pet (2 g per dog, administered orally twice daily on an empty stomach with water), or the placebo group (N = 11), receiving maltodextrin at an equivalent dose.
대조군	-
측정 방법	Subjects were randomly allocated to either the treatment group (N = 12), receiving Exclzyme Pet (2 g per dog, administered orally twice daily on an empty stomach with water), or the placebo group (N = 11), receiving maltodextrin at an equivalent dose.

6. 실험 결과 분석

지표	변화(Δ)	조건 · 유의성
-	-	Exclzyme Pet resulted in a statistically significant reduction in scores for lameness, weight bearing, joint mobility, willingness to hold up contralateral limb, and pain by 51

제안 기전(인과 사슬): Exclzyme Pet resulted in a statistically significant reduction in scores for lameness, weight bearing, joint mobility, willingness to hold up contralateral limb, and pain by 51.96, 46.94, 48.94, 58.0, and 55.56%, respectively and demonstrated clear superiority over placebo. The overall quality of life, mood, and mobility improved significantly in the treatment group over the placebo. Serum C-reactive protein levels decreased markedly by 56.10% in dogs receiving Exclzyme Pet, whereas levels increased by 15.38% in the placebo group, indicating a strong anti-inflammatory effect (p < 0.001)

7. 비판적 평가

강점

In conclusion, Exclzyme Pet demonstrated significant efficacy in reducing clinical signs of arthritis and improving functional outcomes in dogs, with no evident safety concerns during the entire study period

한계 · 의문

표본 크기 및 장기 추적 데이터 부재 가능성

8. 향후 연구 방향

Nevertheless, longer-duration clinical trials with large study population are needed to confirm these findings and further elucidate the mechanisms its therapeutic effects.

9. 결론

A randomized, double-blind, placebo-controlled interventional pilot trial was conducted to evaluate the safety and efficacy of Exclzyme Pet in alleviating clinical symptoms associated with canine arthritis 연구에서 a total of 26 client-owned dogs exhibiting clinical signs of arthritis were enrolled in a 30-day pilot trial, of which 23 completed the study을 통해 exclzyme pet resulted in a statistically significant reduction in scores for lameness, weight bearing, joint mobility, willingness to hold up contralateral limb, and pain by 51. In conclusion, Exclzyme Pet demonstrated significant efficacy in reducing clinical signs of arthritis and improving functional outcomes in dogs, with no evident safety concerns during the entire study period

Keywords

Efficacy, safety, Exclzyme, arthritis, inflammation